- Home
- IBCP vs QURE Comparison
IBCP vs QURE Comparison
Compare IBCP & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- QURE
- Stock Information
- Founded
- IBCP 1864
- QURE 1998
- Country
- IBCP United States
- QURE Netherlands
- Employees
- IBCP N/A
- QURE N/A
- Industry
- IBCP Major Banks
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- IBCP Finance
- QURE Health Care
- Exchange
- IBCP Nasdaq
- QURE Nasdaq
- Market Cap
- IBCP 664.3M
- QURE 725.4M
- IPO Year
- IBCP N/A
- QURE 2007
- Fundamental
- Price
- IBCP $31.22
- QURE $14.49
- Analyst Decision
- IBCP Hold
- QURE Strong Buy
- Analyst Count
- IBCP 3
- QURE 10
- Target Price
- IBCP $36.67
- QURE $37.20
- AVG Volume (30 Days)
- IBCP 71.1K
- QURE 2.1M
- Earning Date
- IBCP 07-24-2025
- QURE 05-09-2025
- Dividend Yield
- IBCP 3.32%
- QURE N/A
- EPS Growth
- IBCP 6.78
- QURE N/A
- EPS
- IBCP 3.14
- QURE N/A
- Revenue
- IBCP $219,516,000.00
- QURE $20,201,000.00
- Revenue This Year
- IBCP N/A
- QURE $60.54
- Revenue Next Year
- IBCP $6.04
- QURE $183.28
- P/E Ratio
- IBCP $10.04
- QURE N/A
- Revenue Growth
- IBCP 6.57
- QURE 6.30
- 52 Week Low
- IBCP $22.53
- QURE $3.73
- 52 Week High
- IBCP $40.32
- QURE $19.18
- Technical
- Relative Strength Index (RSI)
- IBCP 46.49
- QURE 53.84
- Support Level
- IBCP $31.01
- QURE $14.06
- Resistance Level
- IBCP $32.06
- QURE $16.20
- Average True Range (ATR)
- IBCP 0.55
- QURE 0.95
- MACD
- IBCP -0.13
- QURE -0.02
- Stochastic Oscillator
- IBCP 11.67
- QURE 54.02
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.